Immune-mediated thrombocytopenia secondary to suramin.
The authors report a case of suramin-induced immune-mediated thrombocytopenia occurring in a patient on a Phase II protocol for treatment of metastatic renal cell carcinoma. On withdrawal of suramin, the acute and severe thrombocytopenia did not respond initially to plasmapheresis; subsequently, it resolved promptly and dramatically during the administration of intravenous gamma globulin, also coinciding with a decline in suramin blood levels. Results of immunologic and coagulation studies are reported and clinical implications discussed.
Seidman
A D
AD
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Schwartz
M
M
Reich
L
L
Scher
H I
HI
D006801:Humans; D008297:Male; D008875:Middle Aged; D013498:Suramin / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology*
D013498:Suramin